Who
David Alan Campbell
President and CEO
Company insider
Files Form 4 as: President and CEO, Janux Therapeutics.
In numbers
- Trades disclosed
- 27
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $6.7M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 3 Jan 2022
- Last trade
- 31 Jul 2026
- Last filed
- 31 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Jul 2026filed 31 Jul 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code G | —123,840 at $0.00 | filing |
| 31 Jul 2026filed 31 Jul 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code G | —123,840 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code M | $29K7,000 at $4.21 | filing |
| 8 Jul 2026filed 10 Jul 2026 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,000 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,000 at $0.00 | filing |
| 8 Jul 2026filed 10 Jul 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code M | $29K7,000 at $4.21 | filing |
| 2 Jan 2026filed 2 Jan 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Sold | $111K8,072 at $13.73 | filing |
| 2 Jan 2026filed 2 Jan 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —96,600 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —338,100 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —338,100 at $0.00 | filing |
| 2 Jan 2026filed 2 Jan 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Sold | $111K8,072 at $13.73 | filing |
| 2 Jan 2026filed 2 Jan 2026 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —96,600 at $0.00 | filing |
| 7 Jan 2025filed 8 Jan 2025 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Sold | $300K5,000 at $60.00 | filing |
| 2 Jan 2025filed 3 Jan 2025 | JANX Janux Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —283,500 at $0.00 | filing |
| 2 Jan 2025filed 3 Jan 2025 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Code A | —81,000 at $0.00 | filing |
| 24 Dec 2024filed 27 Dec 2024 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.4M25,000 at $56.19 | filing |
| 3 Dec 2024filed 3 Dec 2024 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M15,000 at $67.00 | filing |
| 25 Nov 2024filed 27 Nov 2024 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Sold | $940K18,281 at $51.43 | filing |
| 25 Nov 2024filed 27 Nov 2024 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Sold | $350K6,719 at $52.04 | filing |
| 28 Oct 2024filed 30 Oct 2024 | JANX Janux TherapeuticsBiotechnology | SEC FORM 4 Sold | $740K13,897 at $53.22 | filing |
News
Reviewing Janux Therapeutics (NASDAQ:JANX) & Roivant Sciences (NASDAQ:ROIV)JANX · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name David Alan Campbell; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.